(Q39874212)

English

Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial

scientific article published on May 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

0 references

ankylosing spondylitis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

I-H Song

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

F Heldmann

2

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

M Rudwaleit

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

J Listing

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

H Appel

5

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

J Braun

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

J Sieper

7

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

publication date

1 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

62

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1290-1297

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

ASAS/EULAR recommendations for the management of ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Six months open label trial of leflunomide in active ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Open label trial of anakinra in active ankylosing spondylitis over 24 weeks

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D).

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Assessment of enthesitis in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Intravenous methylprednisolone pulse therapy in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

New approaches of B-cell-directed therapy: beyond rituximab

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Successful treatment of refractory generalized myasthenia gravis with rituximab

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Life threatening steroid-resistant autoimmune anemia successfully treated with rituximab: a case report

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

1 reference

https://api.crossref.org/works/10.1002%2FART.27383

21 January 2018

Identifiers

10.1002/ART.27383

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39874212&oldid=2091878374"